Christine Alewine

List of Publications by Year
in descending order

25 papers	975 citations	623188 14 h-index	610482 24 g-index
25 all docs	25 docs citations	25 times ranked	1445 citing authors

#	Article	IF	Citations
1	Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. Cancer Communications, 2022, 42, 269-272.	3.7	3
2	A phase II trial of the super-enhancer inhibitor Minnelideâ„¢ in advanced refractory adenosquamous carcinoma of the pancreas. Future Oncology, 2022, 18, 2475-2481.	1.1	13
3	Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment. Translational Oncology, 2022, 21, 101440.	1.7	2
4	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS452-TPS452.	0.8	3
5	Furin is not required for processing of mesothelin precursor protein. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118967.	1.9	2
6	Caregiver Exclusion in the Age of COVID: Fighting Cancer With Half the Team. Journal of Clinical Oncology, 2021, 39, 1687-1688.	0.8	8
7	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.. Journal of Clinical Oncology, 2021, 39, 3051-3051.	0.8	3
8	Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Molecular Cancer Therapeutics, 2021, 20, 2082-2092.	1.9	1
9	Molecular mediators of peritoneal metastasis in pancreatic cancer. Cancer and Metastasis Reviews, 2020, 39, 1223-1243.	2.7	29
10	Phase 1 study of the immunotoxin LMBâ€100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer, 2020, 126, 4936-4947.	2.0	31
11	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and antiâ€“PD-1 antibody in patients with mesothelioma and mouse tumor models. Science Translational Medicine, 2020, 12, .	5.8	28
12	Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules, 2020, 10, 973.	1.8	16
13	Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases. Molecular Cancer Research, 2020, 18, 229-239.	1.5	27
14	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2020, 26, 828-836.	3.2	35
15	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9008-9013.	3.3	108
16	Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. JCI Insight, 2019, 4, .	2.3	17
17	Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins, 2018, 10, 447.	1.5	8
18	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patientâ€“Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. Clinical Cancer Research, 2017, 23, 1564-1574.	3.2	32

#	Article	IF	Citations
19	Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Oncotarget, 2017, 8, 9189-9199.	0.8	24
20	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. Journal of Clinical Oncology, 2016, 34, 4171-4179.	0.8	244
21	New Life for Immunotoxin Cancer Therapy. Clinical Cancer Research, 2016, 22, 1055-1058.	3.2	38
22	Advances in Anticancer Immunotoxin Therapy. Oncologist, 2015, 20, 176-185.	1.9	161
23	High mesothelin expression in advanced lung adenocarcinoma is associated withKRASmutations and a poor prognosis. Oncotarget, 2015, 6, 11694-11703.	0.8	66
24	Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers. Molecular Cancer Therapeutics, 2014, 13, 2653-2661.	1.9	68
25	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. PLoS ONE, 2014, 9, e104388.	1.1	8